|
|
|
|
|
Chlorprothixene
drug data and news
Chlorprothixene drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Chlorprothixene | ||
| Brand Names/Synonyms | Alpha-Chlorprothixene; CPT; CPX; Chloroprothixene; Chlorprothixen; Chlorprothixene; Chlorprothixine; Chlorprotixen; Chlorprotixene; Chlorprotixine; Chlothixen; Cis-Chlorprothixene; Iaractan; MK 184; N 714; N 714C; N-714; Paxyl; Rentovet; Tactaran; Taractan; Tarasan; Tardan; Tranquilan; Traquilan; Trictal; Truxal; Truxaletten; Truxil; Vetacalm | ||
| Indication | For treatment of psychotic disorders (e.g. schizophrenia) and of acute mania occuring as part of bipolar disorders. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Chlorprothixene is a typical antipsychotic drug of the thioxanthine class. It has a low antipsychotic potency (half to 2/3 of chlorpromazine). An intrinsic antidepressant effect of chlorprothixene has been discussed, but not proven yet. Likewise, it is unclear, if chlorprothixene has genuine analgesic effects. An antiemetic effect, as with most antipsychotics, exists. It is used in the treatment of nervous, mental, and emotional conditions. Improvement in such conditions is thought to result from the effect of the medicine on nerve pathways in specific areas of the brain. Chlorprothixene has a strong sedative activity with a high incidence of anticholinergic side-effects. Chlorprothixene is structurally related to chlorpromazine, with which it shares in principal all side effects. Allergic side-effects and liver damage seem to appear with an appreciable lower frequency. | ||
| Mechanism Of Action | Chlorprothixene blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis. | ||
| Chlorprothixene News (When available) |
Health Tip: Drugs to Avoid While Breast-Feeding Feb 16, 2006 | ||
| Dosage Forms | TABLET, SYRUP, CONCENTRATE | ||
| Drug_Category | Antipsychotics; Dopamine Antagonists; ATC:N05AF03 | ||
| Absorption | Not Available | ||
| Interactions |
Interactions for Chlorprothixene: Chlorprothixene may increase the plasma-level of concomitantly given lithium. In order to avoid lithium intoxication, lithium plasma levels should be monitored closely. If chlorprothixene is given concomitantly with opioids, the opioid dose should be reduced (by approx. 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of opioids massively. Avoid the concomitant use of chlorprothixene and tramadol (Ultram). Massive seizures may be encountered with this combination. Consider additive sedative effects and confusional states to emerge, if chlorprothixene is given with benzodiazepines or barbituates. Choose particular low doses of these drugs. Exert particular caution in combining chlorprothixene with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. | ||
| Toxicity | Symptoms of overdose include difficulty in breathing (severe); dizziness (severe); drowsiness (severe); muscle trembling, jerking, stiffness, or uncontrolled movements (severe); small pupils; unusual excitement; unusual tiredness or weakness (severe). | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 3-(2-chlorothioxanthen-9-ylidene)-N,N-dimethyl-propan-1-amine | ||
| Chemical Formula | C18H18ClNS | ||
| Molecular Weight | 315.861 g/mol | ||
| Smiles String | CN(C)CCC=C1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl | ||
| Melting Point | 97.5 °C | ||
| Water Solubility | 0.295 mg/L | ||
| State | Solid | ||
| LogP/Hphobicity | 5.654 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Hepatic | ||
| Half Life | 8 to 12 hours | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | Not Available>RXlist | ||
| Sponsored links | |||
| Drug Reference | http://www.drugs.com/cons/Chlorprothixene.html | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00718 | ||
| CAS Registry Number | 113-59-7 | ||
| KEGG Compound ID | C07953 | ||
| PubChem ID | SID:10154 | ||
| PharmGKB ID | PA448967 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | Not Available |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |